How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

345 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial. (Full text)

Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial. The POTENT trial compared the safety and efficacy of tipranavir/ritonavir (TPV/r) to darunavir/ritonavir (DRV/r), each with an optimized background regimen (OBR) in triple-class experienced HIV-1-infected patients with resistance to more than one protease inhibitor (PI).POTENT was a prospective, open-label study of triple-class (PI, non-nucleoside reverse transcriptase (...) weeks. Drug-related adverse events were reported in 21% (TPV/r) and 25% (DRV/r) of patients.TPV/r- and DRV/r-based regimens showed similar short-term safety and efficacy. These data support the use of next-generation PIs such as tipranavir or darunavir with novel class antiretroviral agents (integrase inhibitors, CCR5 antagonists, or fusion inhibitors).

2011 Drugs in R&D PubMed

42. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients. (PubMed)

Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients. This study characterized the pharmacokinetic effects, safety, and antiretroviral activity of three different doses of the nonpeptidic protease inhibitor tipranavir, in combination with ritonavir administered twice daily for 28 days, on a number of triple-combination regimens containing a nonnucleoside reverse transcriptase (...) combinations of tipranavir and ritonavir (1250/100 mg, 750/100 mg, and 250/200 mg) in addition to their antiretroviral (ARV) regimen for the next 22 days. The effects of twice-daily tipranavir and ritonavir combinations on the steady-state pharmacokinetics of the antiretrovirals were assessed by comparing pharmacokinetic parameters at baseline and after 3 weeks of coadministration.No clinically relevant changes were observed in the Cmin, Cmax, or AUC parameters for nevirapine, efavirenz, lamivudine

2010 HIV clinical trials

43. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. (PubMed)

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. Despite being among the most potent protease inhibitors, the use of tipranavir (TPV) is hampered by a high pill burden and frequent side effects compared with other boosted protease inhibitors. A total of 10 patients receiving TPV/ritonavir (TPV/RTV) 500/200 for longer than 6 months were randomized to stay on the same dosing schedule or switch to TPV/RTV 500/100. Although

2010 Therapeutic drug monitoring

44. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. (Full text)

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. The effects of tipranavir/ritonavir (TPV/r) on hepatic and intestinal P-glycoprotein (P-gp) and cytochrome P450 (CYP) enzyme activity were evaluated in 23 volunteers. The subjects received oral (p.o.) caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, and midazolam and digoxin (p.o. and intravenous (i.v.)) at baseline, during the first three

2010 Clinical pharmacology and therapeutics PubMed

45. Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01068925 Recruitment Status : Completed First Posted : February 15, 2010 Last Update Posted : January 25, 2011 Sponsor: GlaxoSmithKline

2010 Clinical Trials

46. Metabolism-Mediated Drug Interactions Associated with Ritonavir-Boosted Tipranavir in Mice (Full text)

Metabolism-Mediated Drug Interactions Associated with Ritonavir-Boosted Tipranavir in Mice Tipranavir (TPV) is the first nonpeptidic protease inhibitor used for the treatment of drug-resistant HIV infection. Clinically, TPV is coadministered with ritonavir (RTV) to boost blood concentrations and increase therapeutic efficacy. The mechanism of metabolism-mediated drug interactions associated with RTV-boosted TPV is not fully understood. In the current study, TPV metabolism was investigated

2010 Drug Metabolism and Disposition PubMed

47. Kaiser Permanente National Cholesterol and Cardiovascular Risk Clinician Guide

or other protease inhibitors Use atorvastatin up to 20 mg, and 40 mg with caution Avoid max dose of any statin Avoid simvastatin and lovastatin Tipranavir Use rosuvastatin up to 20 mg Avoid atorvastatin, simvastatin, and lovastatin HEPATITIS C MEDICATIONS: Current therapy: Guidance: Avoid: Ledipasvir/sofosbuvir Use atorvastatin up to 40 mg Avoid rosuvastatin Simeprevir Use atorvastatin up to 40 mg or rosuvastatin up to 10 mg References: Statin package inserts. Lexicomp HIV medications: http

2018 Kaiser Permanente National Guideline Program

49. Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic

lopinavir saquinavir tipranavir. Other HIV medicines not recommended for co-administration with GRZ/EBR because they may reduce the therapeutic effect of GRZ/EBR are: etravirine elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or alagenamide (fixed-dose combination). Patients receiving opioid-agonist therapy People who inject drugs comprise a major population of patients affected by hepatitis C infection that is rarely included in studies of DAAs. The C-EDGE CO-STAR study evaluated (...) of ALT elevations. GRZ/EBR is contraindicated with OATP1B1/3 inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations, including: rifampicin atazanavir, darunavir, lopinavir, saquinavir and tipranavir ciclosporin. Precautions Caution should be used when co-administering GRZ/EBR with: strong cytochrome P450 3A4 inhibitors (eg, ketoconazole and ritonavir), which may lead to increased concentrations of elbasvir and grazoprevir. HMG-CoA reductase inhibitors

2018 National Prescribing Service Limited (Australia)

50. Kaiser Permanente National Dyslipidemia Clinician Guide

, or saquinavir (ritonavir boosted) Use atorvastatin up to 20 mg, or rosuvastatin up to 20 mg Avoid simvastatin and lovastatin Nonritonavir boosted or other protease inhibitors Use atorvastatin up to 20 mg, and 40 mg with caution Avoid max dose of any statin Avoid simvastatin and lovastatin Tipranavir Use rosuvastatin up to 20 mg Avoid atorvastatin, simvastatin, and lovastatin HEPATITIS C MEDICATIONS: Current therapy: Guidance: Avoid: Boceprevir Use atorvastatin up to 40 mg or rosuvastatin up to 20 mg Avoid

2017 Kaiser Permanente National Guideline Program

51. BHIVA guidelines on the management of HIV in pregnancy and postpartum

population has been excluded [24]. • Darunavir, efavirenz, indinavir, raltegravir and rilpivirine have been shown to have congenital malformation rates within the expected range, and a congenital malformation rate greater than 1.5-fold higher than in the general population has been excluded. • For newer agents (cobicistat, dolutegravir, elvitegravir and tenofovir alafenamide) and a number of less commonly prescribed older compounds (saquinavir, fosamprenavir, enfuvirtide, tipranavir, maraviroc

2019 British HIV Association

53. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. (Full text)

Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. Gender-related differences in the efficacy and safety of ritonavir-boosted tipranavir [tipranavir/ritonavir (TPV/r) 500/200 mg twice daily (b.i.d.)] were evaluated in a subanalysis of the Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir (RESIST) trials. Data from HIV-1-infected women (203; TPV/r = 117

2009 AIDS PubMed

54. Lack of effect of efavirenz on the pharmacokinetics of tipranavir/ritonavir (TPV/r) in healthy volunteers. (Full text)

Lack of effect of efavirenz on the pharmacokinetics of tipranavir/ritonavir (TPV/r) in healthy volunteers. Previously it has been shown that tipranavir-ritonavir (TPV/r) does not affect efavirenz (EFV) plasma concentrations. This study investigates the effect of steady-state EFV on steady-state TPV/r pharmacokinetics. This was a single-center, open-label, multiple-dose study of healthy adult female and male volunteers. TPV/r 500/200 mg twice a day (BID) was given with food for 24 days. After (...) dosing with TPV/r for 10 days, EFV 600 mg once a day was added to the regimen. Intensive pharmacokinetic (PK) sampling was done on days 10 and 24. Validated bioanalytical high-pressure liquid chromatography-tandem mass spectrometry methods were used to determine plasma tipranavir (TPV), ritonavir (RTV), and EFV concentrations. Thirty-four subjects were entered into the study, and 16 subjects completed it. The geometric mean ratios (90% confidence intervals) for TPV and RTV area under the curves, C

2009 Antimicrobial Agents and Chemotherapy PubMed

55. Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers. (Full text)

Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers. To identify pharmacokinetic (PK) drug-drug interactions between tipranavir-ritonavir (TPV/r) and rosuvastatin and atorvastatin, we conducted two prospective, open-label, single-arm, two-period studies. The geometric mean (GM) ratio was 1.37 (90% confidence interval [CI], 1.15 to 1.62) for the area under the concentration-time curve (AUC) for rosuvastatin and 2.23 (90% CI (...) , 1.83 to 2.72) for the maximum concentration of drug in serum (Cmax) for rosuvastatin with TPV/r at steady state versus alone. The GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of atorvastatin and 8.61 (90% CI, 7.25 to 10.21) for the Cmax of atorvastatin with TPV/r at steady state versus alone. Tipranavir PK parameters were not affected by single-dose rosuvastatin or atorvastatin. Mild gastrointestinal intolerance, headache, and mild reversible liver enzyme elevations (grade 1 and 2) were

2009 Antimicrobial Agents and Chemotherapy PubMed

56. Effect of Tipranavir + Ritonavir on Pharmacokinetics of Raltegravir. (Full text)

Effect of Tipranavir + Ritonavir on Pharmacokinetics of Raltegravir. Raltegravir (RAL) is a novel and potent human immunodeficiency virus type 1 integrase inhibitor that is predominantly metabolized via glucuronidation. The protease inhibitor combination tipranavir (TPV) at 500 mg and ritonavir (RTV) at 200 mg (TPV-RTV) has inhibitory and inductive effects on metabolic enzymes, which includes the potential to induce glucuronosyltransferase. Because RAL may be coadministered with TPV-RTV

2009 Antimicrobial Agents and Chemotherapy PubMed

57. An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2009 Clinical Trials

58. Tropical Travel Trouble 009 Humongous HIV Extravaganza

) or Cobicistat is frequently used, The small “r” depicted as a ‘r’ on the end of the 3 letter abbreviations for drugs used can signal ritonavir (i.e. DRV/r) Atazanavir (ATV) Darunavir (DRV) Fos-Amprenavir Lopinavir (LPV) Saquinavir (SAQ) Tipranavir (TPV) Integrase Inhibitors. Blocks the viral DNA integrating into the host’s DNA. Raltegravir (RAL) Elvitegravir (EVG) Dolutegravir (DTG) Bictegravir (BIC) Fusion inhibitors: Attachment inhibitors (CCR5): Fixed dose combinations (not a complete list): Dual

2018 Life in the Fast Lane Blog

59. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014. (Full text)

patients with available resistance data during LPV/r treatment, 27(42.3%) carried DRM to protease-inhibitor, 28 (58.3%) to reverse-transcriptase-inhibitors and 21 (43.7%) to non-reverse-transcriptase-inhibitors. Darunavir/ritonavir, atazanavir-ritonavir and tipranavir/ritonavir presented the highest susceptibility and nelfinavir the lowest.A better lymphocyte recovering occurred when protease-inhibitor was taken as part of a first-line regimen and a higher number of patients reached viral suppression

2017 PLoS ONE PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>